Navigation Links
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:5/31/2008

ng a Cotara Phase II safety and efficacy trial in India in GBM patients at first relapse. In patients treated to date, Cotara appears to be safe and well tolerated.

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody. This monoclonal antibody is designed to bind to a type of DNA that is exposed only on dead and dying cells, and solid tumors have many dead and dying cells at their center. Cotara's targeting mechanism enables it to home in on these cells, delivering its radioactive payload directly to the center of the tumor mass and thereby destroying it "from the inside out," with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method which targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. Cotara is in a Phase I dosimetry trial in GBM patients in the U.S. and a Phase II safety and efficacy trial in GBM patients in India. For more information on the U.S. clinical trials, visit http://www.clinicaltrials.gov

Poster Number: 5B, Abstract No: 2072: S. Shen, R. Lustig, K.D. Judy, J.B. Fiveash, J. S. Shan, "Open-label, dose confirmation and dosimetry study of Interstitial I 131 I-chTNT-1/ B MAB for the t
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
4. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
5. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
6. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
10. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Calif. , April 23 PRO-DEX, INC. (Nasdaq: PDEX ) ... period ended March 31, 2010 on Thursday, April 29, 2010 ... , , ... Eastern Time ( 1:30 Pacific Time ) to discuss operating performance for ...
... VIENNA , April 23, 2010 ... progressed to phase II clinical testing.,It may therefore be possible ... 2012. Indeed the start of this efficacy study comes only ... The company,is active in several disease areas and is currently ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 2Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Cardiac Science (Nasdaq: CSCX ), ... rehabilitation, and informatics products, today announced that it ... Association (WBBA) 2009 Invest Northwest CEO and Investor ... in Seattle. Michael Matysik, senior vice president and ...
... Nausea and Vomiting (PONV)CORONA DEL MAR, Calif., March 11 ... patient,s oxygen status known on a beat-by-beat basis. Not ... say that all patients should have this monitor. No ... ASA Newsletter on their web site between 1983 and ...
... Interactive, Inc. was accepted as an affiliate member of ACA International ... as the American Collectors Association. , ... (Vocus) March ... Ave Ste 100, Plantation, FL 33324-3223, was accepted as an affiliate ...
... Corporation with a Scalable, Powerful System in Support of Patient Safety ... ... Francisco, CA (PRWEB) March 11, 2009 -- The Florida Patient Safety ... certified as a Patient Safety Organization (PSO), has chosen Quantros ...
... a toy drive at Build-A-Bear during annual team-building event , ... ... Cydcor , the leading provider of outsourced, face-to-face sales teams, hosted ... annual corporate kick-off meeting. , ,About 70 participating Cydcor ...
... BC Decker Inc, publisher of the acclaimed general surgical reference, ACS ... MD, FACS as the new Editor-in-Chief , ... Philadelphia, ... the acclaimed general surgical reference, ACS Surgery, is honored to announce ...
Cached Medicine News:Health News:Cardiac Science to Present at the Eighth Annual Invest Northwest Conference 2Health News:American Society of Anesthesiologists (ASA) - Myths About 'Never Ending Pursuit of Patient Safety and Satisfaction' Debunked 2Health News:Business Becomes Affiliate Member of International Trade Association 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 3Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 4Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 5Health News:Cydcor Builds Bears and Bonds in Special Charity Event Benefitting Childrens Hospital Los Angeles 2Health News:New Editor, New Vision for ACS Surgery 2Health News:New Editor, New Vision for ACS Surgery 3
This is a reduced form of the 100 Hue test and L'Anthony New Color Test. The 40 Hue test is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score...
... Farnsworth 100 Hue Test comes boxed in clear ... the potential for test disruption by holding ... Hue test from Richmond Products includes 93 color ... durable laminated score template for copying, a supply ...
... Strep A test is as easy as 1-2-3: ... results. Increase patient satisfaction with rapid information before ... your patient immediately with the appropriate therapy; no ... Use: ,The NOW® Strep A Test is a ...
Single Use Loading Units (SULU's) Knifeless for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Medicine Products: